Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 670.5 JPY 0.39% Market Closed
Market Cap: 606.7B JPY
Have any thoughts about
Santen Pharmaceutical Co Ltd?
Write Note

Santen Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Santen Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Santen Pharmaceutical Co Ltd
TSE:4536
Income from Continuing Operations
ÂĄ26.9B
CAGR 3-Years
38%
CAGR 5-Years
-3%
CAGR 10-Years
4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
ÂĄ290.2B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
ÂĄ250.7B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
ÂĄ155.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
ÂĄ54.6B
CAGR 3-Years
-18%
CAGR 5-Years
-25%
CAGR 10-Years
-6%
No Stocks Found

Santen Pharmaceutical Co Ltd
Glance View

Market Cap
594.1B JPY
Industry
Pharmaceuticals

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,229 full-time employees. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.

Intrinsic Value
2 142.23 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
26.9B JPY

Based on the financial report for Jun 30, 2024, Santen Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 26.9B JPY.

What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
4%

The average annual Income from Continuing Operations growth rates for Santen Pharmaceutical Co Ltd have been 38% over the past three years , -3% over the past five years , and 4% over the past ten years .

Back to Top